The Spanish Agency of Medicines and Medical Devices (Aemps) has suspended most of the clinical trials of hydroxychloroquine as a treatment for the COVID-19 coronavirus, the Agency said in a statement.
The decision was made after WHO, and British experts (the Recovery study) concluded that this antimalarial drug does not help in the treatment of patients with COVID-19.
Aemps draws attention to the fact that no side effects or harm to patients were detected during the studies, and the termination of studies is associated with a lack of positive dynamics. “Preliminary analyses did not reveal any safety issues, and the recommendation to stop recruiting patients for clinical trials is due to the lack of clinical benefit of hydroxychloroquine for hospitalized patients and its use in post-exposure prevention,” the Agency said in a statement.
In Spain, 20 clinical trials are being conducted in 107 medical centers using hydroxychloroquine. Nine of them aimed to determine whether the drug can be used as a preventive measure, six-the impact on patients with a mild degree of disease, five – on patients who were admitted to hospitals with different degrees of disease development.
Of all the studies, only one was completed, some were only at the initial stage, and trials on patients had not yet been conducted.
Aemps allowed the completion of trials already started on patients as prevention and with minor symptoms of the disease, since “there is no definitive data on all combinations of treatment using hydroxychloroquine, treatment of the lungs of patients who were not hospitalized and its use for preventive purposes.”